Anika Therapeutics (ANIK) Operating Leases (2019 - 2025)
Historic Operating Leases for Anika Therapeutics (ANIK) over the last 7 years, with Q3 2025 value amounting to $22.8 million.
- Anika Therapeutics' Operating Leases fell 974.57% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year decrease of 974.57%. This contributed to the annual value of $24.0 million for FY2024, which is 733.55% down from last year.
- As of Q3 2025, Anika Therapeutics' Operating Leases stood at $22.8 million, which was down 974.57% from $23.2 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Operating Leases ranged from a high of $29.7 million in Q2 2022 and a low of $18.8 million during Q1 2022
- Its 5-year average for Operating Leases is $24.5 million, with a median of $25.2 million in 2024.
- In the last 5 years, Anika Therapeutics' Operating Leases surged by 5026.57% in 2023 and then crashed by 1055.65% in 2025.
- Over the past 5 years, Anika Therapeutics' Operating Leases (Quarter) stood at $19.2 million in 2021, then soared by 49.78% to $28.8 million in 2022, then decreased by 10.07% to $25.9 million in 2023, then fell by 7.34% to $24.0 million in 2024, then decreased by 5.13% to $22.8 million in 2025.
- Its Operating Leases was $22.8 million in Q3 2025, compared to $23.2 million in Q2 2025 and $23.6 million in Q1 2025.